Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123) 35.0% ≥complete response. Results from cohort A, which enrolled patients without prior BCMA-directed therapy ( n = 123) are reported. After six cycles, persistent responders switched to biweekly dosing. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. Nature Medicine volume 29, pages 2259–2267 ( 2023) Cite this articleĮlranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |